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Nuclear factor (NF)-κB is the key transcription factor involved in the 
inflammatory responses, and its activation aggravates tumors. Peptidoglycan 
(PGN), a main cell wall component of gram-positive bacteria, stimulates Toll-like 
receptor 2 and activates a number of inflammatory pathways including activation of 
NF-κB. Cannabinoids have been reported to exert anti-inflammatory and 
anti-tumoral actions. The mechanisms underlying these actions, however, are 
largely unknown. The purpose of this study was to investigate whether 
cannabinoids could suppress PGN-induced activation of NF-κB and cell growth via 
cannabinoid receptors in U87-MG human malignant glioma cells. PGN treatment 
induced the phosphorylation of NF-κB and cell proliferation in a 
concentration-dependent manner. The major endocannabinoid 
2-arachidodonoylglycerol prevented the PGN-induced phosphorylation of NF-κB, 
which was reversed by the CB1 cannabinoid receptor antagonist AM281. The 
synthetic cannabinoid WIN55,212-2 abolished the PGN-activated cell growth, and 
this effect was reversed by AM281. Preferential expression of CB1 receptors rather 
than CB2 in these cells was confirmed by reverse transcription-mediated 
polymerase chain reaction experiments and the observation that 
WIN55,212-2-induced morphological changes were completely reversed by AM281 
but not by the CB2 antagonist AM630. Our finding that cannabinoids suppress the 
NF-κB inflammatory pathway and cell growth via CB1 receptors in glioma cells 
provides evidence for therapeutic potential of targeting cannabinoid receptors in the 





Bacteria stimulate the innate immune system of a host and lead to the release of 
inflammatory molecules such as cytokines and chemokines. Lipopolysaccharide 
(LPS) and peptidoglycan (PGN) are the main cell wall components of gram-negative 
and gram-positive bacteria, respectively. LPS and PGN stimulate different Toll-like 
receptors (TLRs), TLR-4 and TLR-2 respectively, and activate a number of 
inflammatory pathways, including activation of the transcription factor nuclear 
factor (NF)-κB (1, 2). NF-κB is the key transcription factor involved in the 
inflammatory responses, and also plays a critical role in tumor cell survival, growth 
and migration. Many of the signal pathways implicated in tumor converge to the 
NF-κB signal. Its activation aggravates tumors, while its suppression inhibits the 
tumor cell growth (3-5). Therefore, NF-κB signaling pathway has emerged as one of 
the attractive targets for treatment of many types of tumors including glioblastoma 
(6).  
 The endocannabinoid system, consisting of two types of G-protein-coupled 
cannabinoid receptors (CB1 and CB2) and their endogenous ligands 
(endocannabinoids) (7), is implicated in a variety of physiological and pathological 
conditions including inflammation and tumor. The CB1 receptor is abundantly 
expressed in the CNS, while the CB2 receptor is predominantly expressed by 
immune cells. Endogenous and exogenous cannabinoids exert anti-inflammatory 
and anti-tumoral actions (8-10). However, the precise mechanisms underlying these 
actions are not fully understood. 
 In the present study, we examined effects of cannabinoids on PGN-induced 
NF-κB activation and cell growth using U87-MG human malignant glioma cells. We 
show here that cannabinoids suppress PGN-induced phosphorylation of NF-κB and 
cell growth in a CB1-dependent manner. Our findings provide a mechanistic basis 
for opening up new therapeutic approaches of treating or preventing brain tumors 
aggravated by the inflammation. 
 
 
Materials and Methods 
Chemicals 
PGN, 2-AG, WIN55,212-2, and Dulbecco’s modified Eagle’s medium (DMEM) were 
obtained from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). AM281 (CB1 
specific antagonist) and AM630 (CB2 specific antagonist) were obtained from 
Calbiochem (La Jolla, CA). Fetal bovine serum (FBS) was obtained from Invitrogen 
3 
 
Corporation (Carlsbad, CA). Anti-phospho-specific NF-κB p65 (Ser536), anti-β-actin, 
and horseradish peroxidase (HRP)-linked anti-rabbit IgG were purchased from Cell 
Signaling Technology, Inc. (Danvers, MA).  
 
Cell culture 
U87-MG human malignant glioma cells were provided by Dr Nakata. The cells were 
maintained in DMEM containing 10% FBS at 37°C in a 5% CO2 incubator. 
 
NF-κB activity assay 
To determine the effect of 2-AG on NF-κB activity, we investigated phospho-NF-κB 
level using western blotting methods. Increase in phospho-NF-κB level indicates the 
amount of NF-κB signaling activation. U87-MG human malignant glioma cells were 
incubated in DMEM containing serum for 24 h and pretreated with 2-AG (1 μM) for 
10 min, and then treated with PGN (1-30 µg/ml) for 16 h. Western blotting analyses 
were performed using phospho-NF-κB p65 (Ser536) antibody and anti-β-actin 
antibody. 
 
Western blotting analysis 
Western blotting was performed as described previously [11].  
 
RT-PCR analysis 
To evaluate the expression patterns of CB1 and CB2 mRNA in the cells, reverse 
transcription-mediated polymerase chain reaction (RT-PCR) was performed as 
follows. Briefly, RNA was extracted from the cells and reverse transcribed by using 
the reverse transcriptase ReverTra Ace (TOYOBO, Tokyo, Japan). PCR-based 
subtype specific gene amplification for CB1, CB2 and β-actin was performed with 
LA Taq (TAKARA, Tokyo, Japan) using the sets of primers as follows: 
5’-caggccttcctaccacttcat-3’ and 5’-accccacccagtttgaacaga-3' for CB1, 
5’-aagccctcgtacctgttcat-3’ and 5’-acagaggctgtgaaggtcat-3' for CB2, and 
5’-atggtgggtatgggtcagaag-3’ and 5’-ctggggtgttgaaggtctcaa-3’ for β-actin. 
 
Microscopic analysis 
U87 cells were seeded on 35 mm dishes at a density of 1 × 103 cells/dish. After 24 hr 
incubation, the cells in DMEM with serum were treated with 1 μM WIN55,212-2, a 
combination of WIN55,212-2 (1 μM) and AM281 (1 μM), or a combination of 
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WIN55,212-2 (1 μM) and AM630 (1 μM) for 72 hr. Morphological changes of cells 
were assessed by light microscopy. 
 
Cell proliferation assay 
Cell proliferation was analyzed using the Cell Counting Kit 8 (Wako, Japan). 
U87-MG human malignant glioma cells were seeded in 96-well plates at a density of 
1 × 103 cells/well. After a 24-h incubation, the cells were treated with PGN, 
WIN55,212-2, or AM281 for 72 h. Next, the cells were incubated with 10 μL WST-8 
for 2 h. Absorbance of the colored formazan product produced by mitochondrial 
dehydrogenases in metabolically active cells was recorded at 450 nm as the 
background value. Cell proliferation was expressed as a percentage of absorbance 
obtained in treated wells relative to that in untreated (control) wells.  
 
Statistical analysis 
Data are presented as means ± SEM from at least three independent experiments. 
Statistical analyses were performed using ANOVA followed by Dunnett’s test, and 




PGN enhances phosphorylation of NF-κB and cell growth 
First, we examined effects of peptidoglycan (PGN), a major cell wall component of 
gram-positive bacteria, on NF-κB activation and cell growth. As shown in Fig. 1A, 
PGN (1-30 µg/mL) increased the level of phosphorylated NF-κB (p65) in a 
concentration-dependent manner, indicating that PGN activates the NF-κB 
signaling pathways in U87 human glioblastoma cells. PGN also accelerated cell 
growth of these cells in a concentration-dependent manner (Fig. 1B). 
 
Endocannabinoid 2-AG inhibits PGN-induced phosphorylation of NF-κB 
We next examined effects of cannabinoids. Anandamide and 
2-arachidodonoylglycerol (2-AG) are the two major endocannabinoids, and activate 
both CB1 and CB2 cannabinoid receptors. Anandamide behaves as a partial agonist 
at these cannabinoid receptors and also activates the vanilloid receptor (TRPV1). 
2-AG acts as a full agonist at cannabinoid receptors and does not interact with 
TRPV1, suggesting that 2-AG is a true natural ligand for cannabinoid receptors (7). 
To examine cannabinoid receptor-dependent effects, therefore, we used 2-AG rather 
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than anandamide as an endocannabinoid. As shown in Fig. 2, PGN (10 
µg/mL)-induced phosphorylation of NF-κB was significantly inhibited by 2-AG (1 
µM). 
 
2-AG inhibits PGN-induced phosphorylation of NF-κB via CB1 receptor 
To test whether cannabinoid receptors are involved in the inhibitory effect of 2-AG,  
we first examined the expression of CB1 and CB2 mRNAs in U87 glioblastoma cells 
using reverse transcription-PCR. The CB1 receptor expression was detectable in 
these cells, but CB2 receptor expression was below the limit of detection (Fig. 3A). 
We then tested effects of the CB1 receptor antagonist AM281, and found that 
AM281 (1 μM) reversed the suppressing effect of 2-AG on PGN-induced NF-κB 
phosphorylation (Fig. 3B). These results indicate that CB1 receptors are involved in 
the effects of 2-AG on the NF-κB signaling pathway. 
 
Cannabinoid agonist WIN55,212-2 affects the cell morphology via CB1 receptor 
To further confirm the presence of functional CB1 receptors in U87 cells, we 
examined effect of cannabinoid receptor antagonists on cannabinoid-induced 
morphological changes. Cell morphology was assessed after 72 hr-treatment with 
drugs. Because of the long incubation time, we used the cannabinoid agonist 
WIN55,212-2 instead of 2-AG, which is easily degraded by endogenous enzymes 
such as monoacylglycerol lipase. Microscopic analysis showed that the treatment 
with WIN55,212-2  (1 µM) affected the cell morphology and increased the number 
of shrunk cells (Figure 4A). The CB1 antagonist AM281 (1 µM), but not the CB2 
antagonist AM630  (1 µM), prevented the WIN55,212-2-induced morphological 
change (Fig. 4A, 4B). These results indicate that functional CB1 receptors are 
expressed in U87 cells, consistent with the above observation (Fig. 3). 
 
WIN55,212-2 inhibits PGN-induced cell proliferation via CB1 receptor  
Finally, we examined the ability of WIN55,212-2 to inhibit PGN-induced cell 
proliferation. When applied alone, WIN55,212-2 (0.01-1 µM) failed to significantly 
affect the cell proliferation (Fig. 5A). However, WIN55,212-2 (1 µM) significantly 
inhibited PGN-induced cell proliferation (Fig. 5B). This effect of WIN55,212-2 was 
reversed by AM281 (Fig. 5B). These results indicate that activation of CB1 







Several lines of evidence show that cannabinoids exert a variety of physiological 
and pharmacological actions (7, 8, 12). Notably, cannabinoids inhibit tumor growth 
and have been proposed as potential anti-tumoral agents (8, 13, 14). However, the 
mechanisms by which cannabinoids prevent tumor progression are still not fully 
understood. Our data suggest the possibility that the anti-tumoral and protective 
action of cannabinoids against PGN-induced inflammatory assaults might be 
associated with their ability to suppress phosphorylation of NF-κB via CB1 receptor 
signaling. 
PGN is a characteristic cell wall component of gram-positive bacteria that 
can stimulate inflammatory signaling in several types of cells. In the present study, 
we found that PGN potently induced NF-κB phosphorylation in human glioma cells 
(Fig. 1A) and enhanced cell growth (Fig. 1B). The NF-κB signal is involved in a 
variety of physiological and pathological events, including inflammation, immune 
responses, and apoptosis. Recently, it has become clear that NF-κB signal pathway 
also has a critical role in cancer development and progression (4, 5, 15, 16). 
Activation of NF-κB has been reported in a wide variety of tumor cells (16). Our 
study showed that 2-AG, one of the endocannabinoids, has an inhibitory effect on 
PGN-induced NF-κB phosphorylation (Fig. 2, 3B), meaning that cannabinoids are 
most likely to prevent tumor progression in inflammation. Indeed, the cannabinoid 
agonist WIN-55212-2 abolished PGN-induced cell proliferation (Fig. 5B). These 
results suggest the therapeutic potential of cannabinoids in 
inflammation-dependent tumor progression. 
TLRs have been established to play an essential role in the activation of 
innate immunity by recognizing specific patterns of microbial components such as 
PGN, LPS, flagellin, CpG DNA and dsRNA derived from virus (1). LPS, an essential 
component of the cell wall of gram-negative bacteria, activates NF-κB signal 
pathway through TLR4. Effects of cannabinoids on LPS-induced NF-κB signal 
pathway have been investigated in several cell types. The prototypic cannabinoid 
Δ9-tetrahydrocannabinol (THC) inhibits LPS-induced NF-κB activation in the 
macrophage cell line RAW 264.7 that expresses CB2 receptors (17), but does not in 
the microglial cell line BV-2 that also expresses CB2 (18). In hippocampal tissue 
including both neurons and glial cells, 2-AG inhibits LPS-induced phosphorylation 
of NF-κB via CB1 receptors (19). The present study demonstrated that 
cannabinoids also inhibit the NF-κB signal induced by the TLR2 agonist PGN 
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through a mechanism involving CB1 receptors (Fig. 2, 3). Because signaling 
pathways of TLR2 and TRL4 for activation of NF-κB are shared by other TLRs (1), 
it is likely that TLR-mediated NF-κB activation may be generally sensitive to 
cannabinoids. The mechanisms underlying suppression of NF-κB signaling by 
cannabinoids are not fully understood. A recent study demonstrated that the effect 
of 2-AG on LPS-induced NF-κB phosphorylation is mediated by peroxisome 
proliferator-activated receptor-γ in hippocampal neurons (20). Further studies are 
needed to determine the molecular mechanisms. 
In conclusion, we showed that cannabinoids prevent PGN-induced 
pathological signal transduction and cell proliferation in U87-MG human malignant 
glioma cells. Our results provide a possibility of cannabinoids as a new therapeutic 
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Fig. 1, Change in the level of phospho-NF-κB (A), and change in cell growth (B) in 
U87-MG human malignant glioma cells after treatment with PGN (1-30 µg/mL). 
Each column represents the mean ± SEM. *P < 0.05 vs untreated controls. 
 
Fig. 2, Change in the level of phospho-NF-κB after treatment with PGN (10 µg/mL) 
or a combination of 2-AG (1 µM) in U87 cells. Each column represents the mean ± 
SEM. *P < 0.01 vs untreated controls. #P < 0.01 vs PGN treatment group. 
 
Fig. 3, Expression of CB1 receptor (A), and change in the level of phospho-NF-κB 
after treatment with PGN (10 µg/mL), a combination of 2-AG (1 µM) and PGN (10 
µg/mL), or a combination of 2-AG (1 µM), PGN (10 µg/mL), and AM281 (1 µM) (B) in 
U87 cells. Each column represents the mean ± SEM. *P < 0.05 vs untreated controls. 
#P < 0.05 vs PGN treatment group. ##P < 0.05 vs PGN and 2-AG treatment group. 
 
Fig. 4, Change in the cell morphology (A) and % of shrunk cells 3 days after 
treatment with WIN55,212-2 (1 µM), a combination of WIN55,212-2 (1 µM) and 
AM281 (1 µM), or a combination of WIN55,212-2 (1 µM) and AM630 (1 µM) (B) in 
U87 cells. Each column represents the mean ± SEM. *P < 0.05 vs untreated controls. 
#P < 0.05 vs WIN55,212-2 treatment group. 
 
Fig. 5, Change in cell growth after treatment with WIN55,212-2 (0-1.0 µM) (A), and 
change in cell growth after treatment with PGN (10 µg/mL), a combination of 
WIN55,212-2 (1 µM) and PGN (10 µg/mL), or a combination of WIN55,212-2 (1 µM), 
PGN (10 µg/mL) and AM281 (1 µM) (B) in U87 cells. Each column represents the 
mean ± SEM. *P < 0.05 vs untreated controls. #P < 0.05 vs PGN treatment group. 
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